Opportunity to take part in a Clinical Trial of a new RA medication- sites in London, Southampton, Oxford and Cardiff

NRAS has been informed about a study which is inviting people living with RA to take part in and we are making you aware of this in case you should wish to take part in the study.

GlaxoSmithKline Research & Development Limited is developing a new medicine which is a potential new treatment for RA. The study is to test the safety and efficacy of GSK2982772, an investigational drug (‘investigational’ means that the drug has not yet been approved for general use).

You may be able to take part in the 203168 Study if you:

Are between 18 and 75 years.

Have been diagnosed with RA and are currently experiencing symptoms.

Are being treated with at least one conventional Disease Modifying Anti-Rheumatic drug (e.g. methotrexate, sulfasalazine, hydroxychloroquine and /or leflunomide).

You would need to be able to travel to London, Southampton, Oxford or Cardiff, taking part about 10 times over about 20 weeks. Please visit nras.org.uk/clinical-trials for further information.

There is no obligation to take part in this study and once you have read more information on the website you can then decide if you would like to take part.

[Mistydawn]

Hi, cannot load the page as per the message. Says it may have been taken down

[EmmaS-NRAS NRAS in reply to Mistydawn]

Thanks Mistydawn, I've now edited the link in Clare's message above so it should work now.

Kind regards

Emma-NRAS

[ITYFIALMCTT]

Information about the specific trial mentioned in OP: nras.org.uk/clinical-resear...

[Nettac]

Only RA or is it also applicable to PsA?

[Hidden]

We only have the information provided by GSK as above - you can email them to ask if PsA is being considered at which ever centre is nearest you.

If you are interested in participating in this study or would like more information, please contact:

[e-mail] or 020 3313 8070 at Hammersmith Hospital, London

[e-mail] or 02920 748 251 at University Hospital of Wales, Cardiff

[e-mail] or 023 8120 5279 at Southampton General Hospital

[e-mail] at University of Oxford